INCY
Incyte · Health Care
8.1%
typical move (median |reaction| of last 8)
2026-10-27 pre · likely
next expected · estimated from pattern
12
scored events
Last eight reactions
2024-10-29 → 2026-07-28
| date | session | reaction | |move| | excess 5s | excess 20s |
|---|---|---|---|---|---|
| 2026-07-28 | pre | +9.2% | 9.2% | -11.2% | -3.5% |
| 2026-04-28 | pre | +2.2% | 2.2% | -2.0% | -5.8% |
| 2026-02-10 | pre | -8.3% | 8.3% | +3.7% | -3.1% |
| 2025-10-28 | pre | -1.6% | 1.6% | +14.0% | +16.9% |
| 2025-07-29 | pre | +10.2% | 10.2% | +1.6% | +7.0% |
| 2025-04-29 | pre | +1.7% | 1.7% | -2.2% | +1.3% |
| 2025-02-10 | pre | -7.9% | 7.9% | +3.3% | +7.7% |
| 2024-10-29 | pre | +12.0% | 12.0% | +5.9% | -1.6% |
Source filings
2026-07-28 · 8-K press release
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates Total revenue of $1.67 billion and total net sales of $1.49 billion in the second quarter of 2026, an increase of 38%
2026-04-28 · 8-K press release
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates Total revenue of $1.27 billion and total net sales of $1.10 billion in the first quarter of 2026, an increase of 21% a
2026-02-10 · 8-K press release
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results Total revenue of $1.51 billion (+28% Y/Y) in the fourth quarter 2025 and $5.14 billion (+21% Y/Y) for the full year 2025 Total net pr
2025-10-28 · 8-K press release
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates Total revenues of $1.37 billion in the third quarter of 2025, reflecting 20% growth compared to the third quarter of 2
2025-07-29 · 8-K press release
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs – Total revenues of $1,216 million in the second quarter (Q2'25) (+16% Y/Y); total product revenues o
2025-04-29 · 8-K press release
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs – Total revenues of $1,053 million in the first quarter (Q1'25) (+20% Y/Y); total product revenues of
2025-02-10 · 8-K press release
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones – Total revenues of $1.2 billion (+ 16% Y/Y) in the fourth quarte
2024-10-29 · 8-K press release
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs – Total revenues of $1,138 million in the third quarter (Q3'24) (+24% Y/Y) – Jakafi ® (ruxolitinib) ne